By David Ostrowsky – On the prescription drug front, the recent launch of TrumpRx has been all the rage on the federal level, but not to be overlooked, there have been some fascinating state-specific developments worth examining.
By Naga Vivekanandan Esq. – Medicare has spent years watching GLP-1 drugs move from a promising diabetes therapy to one of the most consequential drivers of prescription drug spending. That shift has been fueled by strong clinical results, expanding indications, and unprecedented demand.
From KFF Health News Network – Their latest podcast, What the Health, Congress appears ready to approve a spending bill for the Department of Health and Human Services for the first time in years, minus the dramatic cuts proposed by the Trump administration.
The U.S. Food and Drug Administration announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases. In a new draft guidance, the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing.
From KFF Health News Network – Their latest podcast, What the Health, As long predicted, much of the federal government shut down on Oct. 1, after Congress failed to agree on spending bills that keep most programs running. Republicans need at least a handful of Democratic votes to pass spending bills in the Senate.
From KFF News Network – Their latest podcast, ‘An Arm And A Leg’, This week, In response to the high price of prescription drugs, “An Arm and a Leg” asked listeners to share their strategies for getting the medicine they need at prices they can manage.
From KFF News Network – Their latest podcast, ‘An Arm And A Leg’, This week, About 3 in 10 adults reported not taking their medicines as prescribed at some point between July 2022 and July 2023 because of the cost, according to a KFF survey. So, this year, “An Arm and a Leg” asked listeners: What strategies have you used when you’ve been struck by pharmacy sticker shock?
From KFF Health News Network – Their latest podcast, What the Health, After narrowly passing a budget resolution this spring foreshadowing major Medicaid cuts, Republicans in Congress are having trouble agreeing on specific ways to save billions of dollars from a pool of funding that pays for the program without cutting benefits on which millions of Americans rely.
The Centers for Medicare & Medicaid Services announced that agreements have been signed with manufacturers of the 15 drugs covered under Medicare Part D selected for the second cycle of the Medicare Drug Price Negotiation Program.
HHS announces 15 additional drugs selected for Medicare Drug Price Negotiations in continued effort to lower prescription drug costs for seniors. Building on the success of the first round of negotiations, the aim is to lower prices for some more of the costliest prescription drugs.
©2026 Answers Media Company, LLC